Published online Oct 8, 2015. doi: 10.4254/wjh.v7.i22.2389
Peer-review started: February 2, 2015
First decision: May 13, 2015
Revised: September 6, 2015
Accepted: September 16, 2015
Article in press: September 18, 2015
Published online: October 8, 2015
Processing time: 244 Days and 7.5 Hours
Chronic infection with hepatitis delta virus (HDV) has lately regained clinical importance because of the recent evidence of increasing prevalence in several European countries, due to immigration from highly endemic areas. HDV requires the mandatory presence of hepatitis B virus (HBV) for propagation to hepatocytes. It is transmitted by the same routes of HBV and it can be acquired either by co-infection (simultaneous transmission of the two viruses) or super-infection (acquisition of HDV by an already chronic carrier of HBV). As a consequence, every HBV carrier is potentially at risk for HDV superinfection. Since the clinical course of super-infection can be severe, early diagnosis of HDV infection is necessary.
Core tip: The re-appearance of hepatitis delta virus infection in developed Countries has risen new interest on one of the most severe forms of viral hepatitis in humans. The lack of research on the subject for about two decades is responsible for the present unavailability of specific and efficient antiviral treatments against hepatitis delta virus. This review focuses on what is known up today and what still needs to be done.